Sector News

Merck’s Mammen joins Johnson & Johnson to head R&D

June 9, 2017
Life sciences

Mathai Mammen, M.D., Ph.D. is leaving Merck after a little more than a year at the company to take up a position at Johnson & Johnson. The Theravance Biopharma co-founder is set to takeover from William Hait, M.D., Ph.D. as global head of R&D, freeing his predecessor to start a new role overseeing J&J’s prolific partnering operation.

Mammen will join J&J later this month and transition into his new post over the rest of the year. The formal handover is due to take place on January 1. After that, Mammen will serve as global head of R&D at J&J’s Janssen drug development arm. And Hait will start in a newly-created post that gives him oversight of the biotech incubators and network of global partnerships built up by Johnson & Johnson Innovation.

The reshuffle tasks Mammen with continuing Hait’s work to turn J&J into one of the more effective Big Pharma R&D shops. Mammen and the pipeline he oversees will need to keep up this level of performance if J&J is to hit its recently-set targets for new approvals and sales growth.

Hait is leaving Mammen with a pipeline he recently called “one of the most robust and sustainable … in the industry.” And in his new position he will continue to play a role in ensuring the pipeline is stocked with promising prospects. Hait’s new title of global head, J&J external innovation gives him responsibility for the company’s JJDC VC wing, JLABS startup incubators and the innovation centers it has set up in Boston, MA, Menlo Park, CA, London, United Kingdom and Shanghai, China.

These initiatives have enabled J&J to establish relationships with—and keep tabs on the progress of—a large number of young companies.

Appointing Hait to oversee the growing operation reiterates the unit’s importance to J&J. It is now 10 years since Hait left academia to join J&J. When Hait arrived at J&J to head up hematology and oncology R&D, the company was in the middle of consolidating the disparate teams working across its many units in those therapeutic areas. Hait oversaw that work and a period in which J&J established itself as a company to watch in oncology through drugs such as Darzalex.

Mammen’s exit deprives Merck of a SVP it only recently lured away from Theravance. Mammen left Theravance in March 2016 to take up a position at Merck that gave him a leading role in its research in key therapeutic areas, including cardiovascular and metabolic disease, immunology, oncology and immuno-oncology.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.